-
Cantor Cuts Illumina's Price Target To $155, Positive On Pacific Biosciences Of California
Tuesday, October 11, 2016 - 8:57am | 300Read More...Shares of Illumina, Inc. (NASDAQ: ILMN) plunged 26 percent in Tuesday's pre-market after the company slashed its third quarter sales estimate on larger than expected drop in high throughput sequencing instruments. The company now sees third quarter revenue of about $607 million, down from...
-
Cantor Fitzgerald Upgrades Trovagene To Buy, Bullish On Clinical Business
Monday, August 8, 2016 - 9:14am | 307Read More...TrovaGene Inc’s (NASDAQ: TROV) urine-based technology allows for a differentiated approach to cancer detection and monitoring, positioning the company to be “a key player in the cancer diagnostics market,” Cantor Fitzgerald’s Bryan Brokmeier said in a report. He maintained...
-
Cantor Still Recommending A Buy For T2 BioSystems
Monday, June 20, 2016 - 4:00pm | 249Read More...Cantor Fitzgerald maintained its Buy rating on T2 Biosystems Inc (NASDAQ: TTOO) following the American Society for Microbiology (ASM) Microbe 2016 Conference. Moreover, the company reports that the T2Bacteria trial remains on track, which the brokerage believes may support T2Dx adoption in the...
-
Veracyte Now In Position For A Rate Increase In 2018
Monday, June 20, 2016 - 3:58pm | 152Read More...Cantor Fitzgerald analyst Bryan Brokmeier told investors to buy shares of Veracyte Inc (NASDAQ: VCYT). "The shift to market-based pricing and clarity on the implementation timeline improves transparency and recognizes the value innovative tests bring to the market," Brokmeier said....
-
Departure Of TrovaGene CCO Creates Near-Term Risks; Cantor Downgrades Stock
Monday, April 25, 2016 - 4:53pm | 386Read More...Shares of TrovaGene Inc (NASDAQ: TROV) plunged 24 percent after Cantor Fitzgerald downgraded the company to Hold from Buy, saying that although the new CEO hire is positive, the departure of CCO is a "significant negative" for the company. TrovaGene, a developer of cell-free molecular...
-
Maxim Group Reiterates on Sequenom Following Strong 3Q13 Results
Friday, November 8, 2013 - 12:17pm | 191Read More...In a report published Friday, Maxim Group analyst Bryan Brokmeier reiterated a Buy rating and $6.00 price target on Sequenom (NASDAQ: SQNM). In the report, Maxim Group noted, “We recommend that investors Buy shares of SQNM following the strong 3Q13 results. Volume was strong as sales in New York...
